WallStreetZenWallStreetZen

NYSE: PEN
Penumbra Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Penumbra earnings were $164.0M for the trailing 12 months ending Sep 30, 2025, with 370% growth year over year. The latest PEN earnings report on Sep 30, 2025 announced Q3 2025 earnings of $45.9M, up 1.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PEN reported annual earnings of $14.0M, with -84.6% growth. The next PEN earnings date is Feb 24, 2026.

PEN past earnings growth

How has PEN's earnings growth performed historically?

Company
370%
Industry
49.9%
Market
53.64%
PEN's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
PEN's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
PEN's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

PEN earnings history

Current Revenue
$1.3B
Current Earnings
$164.0M
Current Profit Margin
12.3%
PEN's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

PEN Return on Equity

Current Company
13.1%
Current Industry
13.3%
Current Market
35.1%
PEN's Return on Equity (13.1%)... subscribe to Premium to read more.
High Return on Equity Performance

PEN undefined

Current Company
10%
Current Industry
7.8%
PEN is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when PEN announces earnings.

PEN undefined

Current Company
11.8%
Current Industry
8.5%
PEN has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PEN vs Medical Device Stocks

TickerEBITDAEarningsY/Y EarningsEPS
PEN$203.23M$164.03M+46.83%$4.23
GMED$731.92M$423.78M+26.66%$3.13
ALGN$762.38M$378.40M-25.22%$5.17
SNN$1.29B$412.00M+4.64%$1.12
BIO-$793.53M-$675.90MN/A-$24.21
View Top Medical Device Stocks

PEN earnings dates

Next earnings date
Feb 24, 2026

Penumbra Earnings Reports & History FAQ

What were Penumbra's earnings last quarter?

On PEN's earnings call on Invalid Date, Penumbra (NYSE: PEN) reported Q3 2025 earnings per share (EPS) of $1.17, up 53.95% year over year. Total PEN earnings for the quarter were $45.85 million. In the same quarter last year, Penumbra's earnings per share (EPS) was $0.76.

If you're new to stock investing, here's how to buy Penumbra stock.

When does Penumbra report earnings?

The next PEN earnings call is Invalid Date. Add PEN to your watchlist to be reminded of Penumbra's next earnings date.

Is Penumbra profitable or losing money?

As of the last Penumbra earnings report, Penumbra is currently profitable. Penumbra's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $164.03 million, a 374.79% increase year over year.

What was PEN's earnings growth in the past year?

As of Penumbra's earnings date in Invalid Date, Penumbra's earnings has grown 370% year over year. This is 320.1 percentage points higher than the US Medical Devices industry earnings growth rate of 49.9%. PEN earnings in the past year totalled $164.03 million.

What are Penumbra's earnings expectations?

The current EPS estimate for Penumbra's earnings report in Invalid Date is $1.12.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.